AKERS BIOSCIENCES INC: Distribution Agreement

Embargoed: 0700hrs 30 October 2006 


                              Akers Biosciences Inc.                             
                            ("Akers" or the "Company")                           


                       Major Distribution Agreement                           
Thorofare, NJ, USA-October 30, 2006--Akers Biosciences Inc. (LSE:AKR) is
pleased to announce that it has signed an agreement with Pulse Marketing Corp.
("Pulse") of Portland, Oregon, USA for the marketing and distribution of Akers'
home cholesterol and free radical tests to direct sales companies, most of whom
are members of the Direct Selling Association. The agreement includes
development funds to be paid to Akers to modify the tests to Pulse's
specifications, and then provides for manufacturing of the products by Akers
for Pulse. Pulse, whose distribution reaches over 1 million independent
business owners in North America alone, intends to market the products as soon
as the development phase is completed, which is targeted for March 2007. 
Until now Akers has not marketed these products in the U.S. to the direct sales
marketplace. This agreement with Pulse will significantly increase the number
of representatives marketing the product and the regions in which Akers is able
to penetrate. 
Dr. Ray Akers, CEO of Akers Biosciences said, "Today's agreement represents a
significant step in our strategy to penetrate a large segment of the U.S. home
healthcare market. There is a clear medical need for our breakthrough tests for
cholesterol and free radicals, and this agreement fits nicely with the trends
in wellness and health awareness among U.S. consumers. This alliance with Pulse
Marketing will make our product more widely available to consumers across the
U.S., and will significantly increase our share of voice in the marketplace." 
Information on the Tri-Cholesterol and Free Radical Tests 
Cholesterol levels are directly related to the risk of cardiovascular disease.
The Tri-Cholesterol Test Kit is the only FDA-approved rapid assay that provides
a complete cholesterol profile of the patient, with semi-quantitative
determinations of high-density lipoprotein (HDL) cholesterol, low-density
lipoprotein (LDL) cholesterol, and total cholesterol levels in whole blood
obtained from a finger stick. This complete cholesterol test panel has been
designed in a test card format; an enzymatic color reaction from a single drop
of blood produces results in approximately three minutes. Akers will modify the
test under this agreement to work with a non-invasive sample, such as
transdermal fluid or saliva, instead of whole blood. 
The Free Radical test measures the level of lipid peroxides in urine, which is
an indication of free radical activity in a person's metabolism. Free radicals
are associated with many disease processes, including cardiovascular,
neurological, and immune systems diseases. Elevated levels of lipid peroxides
indicate a need for increased levels of anti-oxidants, which can be provided in
certain nutritional supplements. 
Pulse Marketing Corp. 
Pulse, and its affiliate Beanstalk Partners, are leading marketing
organizations for direct selling companies such as Quixtar Inc., Melaleuca,
Inc., Mannatech, Inc., and PrePaid Legal, Inc. Pulse distributes products into
these organizations, and creates the sales and marketing initiatives for these
companies. Pulse's products reach over 1 million independent business owners in
North America alone. 
Akers Biosciences 
Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of
care screening and testing products designed to bring healthcare information
both rapidly and directly to the patient or healthcare provider. The Company
has advanced the science of diagnostics while responding to major shifts in
healthcare through the development of several proprietary platform
technologies. The company's state-of-the-art rapid diagnostic assays can be
performed virtually anywhere in minutes when time is of the essence. Akers has
aligned with major healthcare companies and high volume medical products 
distributors to maximize product offerings, and to be a major worldwide
competitor in diagnostics. Additional information on the Company and its
products can be found at www.akersbiosciences.com. 
Enquiries: 
Dr. Ray Akers     Chief Executive Officer, Akers Biosciences,  020 7917 9476    
              Inc.                                                         
Paul Freedman                                                  001 856 848 8698 


                  Chief Financial Officer, Akers Biosciences,                  
                  Inc.                                                         


                                                                           
Xavier DeMol      Robert W. Baird, Ltd.                        020 7667 8246    
                                                                           
Bill Roberts      CTC, Inc.                                    001 937 434 2700 
                                                                           
Ben Simons        Hansard Communications                       020 7245 1100    
 
END 
-0- Oct/30/2006  7:01 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.